




Vision – Singaporean Immuno-therapy biotech unicorn

Mission – vie for 2 potential listings in 2021 and 1 intended major listing in 2023

# Immunity – The Shield Against Illnesses (or Death)



# 1 FEGO Company – 2 Strategic Fronts / 3 Business Units

**FEGO Biotech Pte Ltd** (2016) is an **immuno-therapy** company addressing viral infections, skin problems, chronic ailments, auto-immune disorders and early cancer diseases

PHARMACEUTICALS

NUTRACEUTICALS

Biosimilars  
(prescriptive)

Car-T / Cell therapy  
(treatment)

Smart Supplements  
(prevention)


The proprietary extraction technology and many other associated IPs are protected under Singapore Patent Application No. 10201802979V

# 1/3 Integrated Immuno-healthcare In Age Management



**Immuno-EBN smart supplements**

- Early 2018
- G' NEST Premium
- G' NEST upgrades for different mkt segments
- RNA diagnostics & DNA tools for big data analysis
- 2<sup>nd</sup> line production in China for hospitals (2021)




**Biosimilar Immuno-drugs**

- Late 2020
- > 7 joint govt-researched biosimilars (wip)
- Co-development with foreign scientists
- Businesses with major global clients
- 2 major contracts in early 2021 expected



**Car-T & FDA Clinical Trials**

- Plan mid-2021 for Car-T advance research
- In discussion with leading authorities & hospitals
- FDA Phase 3 trials (wip) 2020/21 for colorectal cancer and liver cancer treatments



# Investment Commitments Into Our Companies

项目选址实景图

中国—新加坡生物科技合作项目



国际合作联合实验室选址南宁片区

项目地址实景图

中国—新加坡生物科技合作项目



IAC加工贸易(生产线)拟选址钦州港片区

## 中新合作生物加工技术项目

专利技术发明人：林家明 博士（新加坡）

项目顶层设计指导专家：张永贵

项目对接统筹指导：邱陵

项目对接整合：梁赞伟

南沙投资指导：黄文奇（广州南沙经济技术开发区招商局）

项目合作指导：卢建旭（骏德商业集团）

1. Chinese government has ploughing in already more than RMB35 million on infrastructure.
2. Committed RMB100 million in initial capital and RMB1 billion in total.
3. Committed to sales of 1 million boxes each for G' NEST and RENEAU

# Summary of World's First 7 Scientific Discoveries



## Enhance Immunity Against Infection

Restrict dengue viruses replication upon direct application to macrophages cell (immune cells in human beings).



## Better Management Of Acute Diseases

This discovery as an immunological concentrate could induce macrophages to produce titrated cytokines in culture.



## Enhance Prevention Of Infection And Cancer

Cytokines are "immuno-modulating" molecules that balance and regulates our immune system responses in our body.



## Sustainable B-cell Cytokine Production

This discovery as an immunological concentrate could have a dose-dependent effects on B-cells for cytokine production, including sustainable and prolonged effects.



## Better Management Of Cancer And Influenza

The immunological concentrate could induce phosphorylation which activates IRF3 to enhance anti-cancers and anti-viral suppression properties.



## Regulate Immune System

The compound could induce NF- $\kappa$ B immune regulating pathway plays a key role in regulating the immune response against infection, reducing the chance of acute infection attacks or on the contrary, cytokine storms.



## Balance Inflammatory Factors


As an immunological formulation, this concentrate balances the expression of pro-inflammatory and anti-inflammatory molecules in the body, and titrates the number of inflammatory cells, thus reducing immune over-reactions as well immune under-reactions.



# 2/3 Integrated Immuno-healthcare In Age Management



- Immuno-EBN smart supplements
- Early 2018
  - G' NEST Premium
  - G' NEST upgrades for different mkt segments
  - RNA diagnostics & DNA tools for big data analysis
  - 2<sup>nd</sup> line production in China for hospitals (2021)



- Biosimilar Immuno-drugs
- Late 2020
  - > 7 joint govt-researched biosimilars (wip)
  - Co-development with foreign scientists
  - Businesses with major global clients
  - 2 major contracts in early 2021 expected




- Car-T & FDA Clinical Trials
- Plan mid-2021 for Car-T advance research
  - In discussion with leading authorities & hospitals
  - FDA Phase 3 trials (wip) 2020/21 for colorectal cancer and liver cancer treatments



# Biopharma Biosimilars Growth 60% Worth USD 35.032 Billion

## GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET Size & Forecast (2013-2020)



- ### GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY SERVICES
- Contract Research and Manufacturing Services (CRMS)
  - Clinical trials



- ### GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY TECHNOLOGY
- Monoclonal Antibodies (MAb) Technology
  - Nuclear magnetic resonance (NMR) technology
  - Electrophoresis
  - Western Blotting
  - Recombinant DNA Technology (rDNA technology)
  - Chromatography
  - Mass Spectrometry
  - Bioassay


### GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET DYNAMICS

- #### Drivers
- Growing pressure to reduce healthcare expenditure
  - Various blockbusters going off patent
  - High prevalence of chronic diseases among aging population
  - Favorable intervention from the developing economies
- #### Restraints
- High initial investment in research and development
  - Stringent regulations in developed economies to restrict investment
  - Medical Efficacy and Patient Safety

- ### GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY APPLICATIONS
- Blood disorders
  - Oncology diseases
  - Chronic and autoimmune diseases
  - Growth hormone deficiencies

- ### GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY PRODUCT TYPE
- Recombinant Non-Glycosylated Protein
  - Recombinant Glycosylated Protein
  - Peptides

#### Biosimilar Is A Drug



For More Details See Table Of Contents



# World's Best Selling Biosimilar Drugs



**TOPFOREIGNSTOCKS.COM**  
Your Money. Your Future.

HOME FOREIGN ADS LIST DOWNLOADS INDICES ETF LISTS ABOUT US EDUCATION STOCK LISTS DIVIDEND HISTORY

## The Top 15 Drugs by Sales in 2018: Chart

Posted by David Hunter on 21 August 2019, 9:21 am

The chart below shows the top 15 drugs by revenue in 2018. Abbvie's (ABBV) Humira was the top selling drug with total sales of over \$18 billion.

[Click to enlarge](#)



<p><b>1</b> <b>Humira®</b> (adalimumab) <b>Abbvie</b> 2018 Sales: <b>\$18.936 billion</b> 2017 Sales: <b>\$18.427 billion</b> CHANGE <b>▲ 8.2%</b></p>	<p><b>2</b> <b>Eliquis®</b> (apixaban) <b>Bristol-Myers Squibb and Pfizer</b> 2018 Sales: <b>\$9.872 billion</b> (\$4.888 BMS + \$3.434B Pfizer)* 2017 Sales: <b>\$7.395 billion</b> (\$4.072B BMS + \$2.521B Pfizer)* CHANGE <b>▲ 33.5%</b></p> <p><small>* Pfizer Acquired Eliquis from Bristol-Myers Squibb in 2017</small></p>	<p><b>3</b> <b>Revlimid®</b> (lenalidomide) <b>Celgene</b> 2018 Sales: <b>\$9.605 billion</b> 2017 Sales: <b>\$8.167 billion</b> CHANGE <b>▲ 18.3%</b></p>
<p><b>4</b> <b>Opdivo®</b> (nivolumab) <b>Bristol-Myers Squibb and Ono Pharmaceutical</b> 2018 Sales: <b>\$2.570 billion</b> (\$1.731B BMS + \$833M Ono) 2017 Sales: <b>\$5.763 billion</b> (\$4.848B BMS + \$915M Ono) CHANGE <b>▲ 31.4%</b></p>	<p><b>5</b> <b>EG-1962</b> (mitolriptin microparticles) <b>Merck &amp; Co.</b> 2018 Sales: <b>\$2.171 billion</b> 2017 Sales: <b>\$3.809 billion</b> CHANGE <b>▲ 88.3%</b></p>	<p><b>6</b> <b>Enbrel®</b> (etanercept) <b>Amgen and Pfizer</b> 2018 Sales: <b>\$7.126 billion</b> (\$5.014B Amgen + \$2.112B Pfizer)* 2017 Sales: <b>\$7.885B</b> (\$5.412B Amgen + \$2.452B Pfizer)* CHANGE <b>▼ -9.6%</b></p> <p><small>* Pfizer Acquired Enbrel from Amgen in 2017</small></p>
<p><b>7</b> <b>Herceptin®</b> (trastuzumab) <b>Roche (Genentech)</b> 2018 sales: <b>\$6.981 billion</b> (CHF 6.982 billion) 2017 sales: <b>\$7.013 billion</b> (CHF 7.014 billion)</p>	<p><b>8</b> <b>Avastin®</b> (bevacizumab) <b>Roche (Genentech)</b> 2018 Sales: <b>\$6.547 billion</b> (CHF 6.549 billion) 2017 Sales: <b>\$6.686 billion</b> (CHF 6.688 billion)</p>	<p><b>9</b> <b>Rituxan®</b> (rituximab) <b>Roche (Genentech) and Biogen*</b> 2018 Sales: <b>\$6.750 billion</b> (CHF 6.753 billion) 2017 Sales: <b>\$7.298 billion</b> (CHF 7.300 billion)*</p>

# Applications of Biosimilars

Molecules	Trade Name	Own by	Treatments
Rituximab	Rituxan/ Mabthera	Genentech/Biogen (US) / Roche	Rheumatoid Arthritis, B Cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, autoimmune diseases and cancer
Trastuzumab	Herceptin	Genetech, Roche	Breast Cancer, Gastric Cancer
Bevacizumab	Avastin	Roche (Genentech)	Eye, Kidney, lung, brain, cervical, fallopian tube, ovarian, abdomen, colon, and rectal cancers
Denosumab	Prolia, Xgeva	Amgen,	Osteoporosis, bone tumor, treatment induced bone loss
Ipilimumab	Yervoy	BMS	Metastatic Melanoma
Ramucirumab	Cyramza	Eli Lilly	Metastatic gastric adenocarcinoma, metastatic non-small cell lung cancer Metastatic colorectal cancer

# Other Biosimilars In FEGO Biotech Pipeline


Molecules	Trade Name	2016 Revenue	2017 Revenue	Patent Status	2018 Sales USD	2019 Sales USD
Rituximab	Rituxan (US), MabThera (EU)	USD 7.3b	USD 7.9 Bn	US: <b>Expired</b> Sept 2016 EU: <b>Expired</b> Nov 2013	7.00 Bn	7.10 Bn
Trastuzumab	Herceptin/Ogivri (BS)	USD 7.0b	USD 7.4 Bn	US: <b>Expired</b> Jun 2019 EU: <b>Expired</b> Aug 2015	6.76 Bn	6.62 Bn
Bevacizumab	Avastin (Roche/Genentech)	USD 7.2b	USD 7.1 Bn	US: <b>Expired</b> July 2019 EU: In Force till Jan 2022	7.47 Bn	7.79 Bn
Denosumab	Prolia & XGeva	USD 3.1b	USD 3.5b	US: In Force till Feb 2025 EU: In force till Jun 2022	NA	NA
Ipilimumab	Yervoy	USD 1.0b	USD 1.2b	US: In Force till 2022 EU: <b>In Force till 2020</b>	1.31 Bn	NA
Ramucirumab	Cyramza	USD 614m	USD 758m	US: In Force till Nov 2025 EU: In Force till May 2023	NA	NA

# 3/3 Integrated Immuno-healthcare In Age Management



## Immuno-EBN smart supplements

- Early 2018
- G' NEST Premium
- G' NEST upgrades for different mkt segments
- RNA diagnostics & DNA tools for big data analysis
- 2<sup>nd</sup> line production in China for hospitals (2021)



## Biosimilar Immuno-drugs

- Late 2020
- > 7 joint govt-researched biosimilars (wip)
- Co-development with foreign scientists
- Businesses with major global clients
- 2 major contracts in early 2021 expected



## Car-T & FDA Clinical Trials

- Plan mid-2021 for Car-T advance research
- In discussion with leading authorities & hospitals
- FDA Phase 3 trials (wip) 2020/21 for colorectal cancer and liver cancer treatments



# FEGO Biotech Is a Sexy Investment – prudent investors

1. Company has many proprietary capabilities in physical scientific assets
2. Leverages and work with professional scientists and doctors worldwide
3. Growth in-roads in populous countries such as China and India for clinical studies and growth, be it food/dietary supplements or cancer treatments (and iPSCs)
4. Works out commercially viable business models in the shortest possible time
5. Aspires to be a Singapore IPO unicorn in ASX (planning), Nasdaq (planning) or others
6. Singapore government support



# Leadership Team



**Dr Lim Kah Meng**

Founder & CEO. PhD in Biological Science, Stem Cells & Cancer Research. 20 years in business entrepreneurial management and R&D experience. A serial investor with IPO focus.



**Dato Dr Derek Goh**

Founder & Group CEO, Serial Systems Ltd; Singapore's largest listed company electronics component distributors and diversified interests in healthcare, safe food and hospitality.



**Sethu Ragupathy**

Director, Biologics. With 26 years of Pharma research, in Life Science with SGS & international companies. He had Previously worked in India, UK, Central Africa and S. Africa



Executive Advisor of Medical Affairs with 18+ years as Medical senior executive in pharma and medical industries at Covidien, Schering Plough Covance, Glaxo Wellcome. Ex CEO of Gleneagles Singapore, Farrer Park Hospital. Head of Healthcare Invt (Pavilion Capital)



**Linus Ng**

Legal Counsel. Extensive experience in corporate finance & governance, regulatory and compliance, fund raising, IPOs and reverse takeover, mergers and acquisitions



**Kenneth Lam**

General Manager. Over 30 years with Fortune 500 banking & finance, real estate assets, risk management, manufacturing, and international work in management consulting



**Nicholas Tan**

Visionary technopreneur with global business experience and experimental flight test. He believes companies have to adopt new technologies and business models, not just to compete, but to survive. He founded Biggworld company to solve problems of fake products and reviews with blockchain.



**Sam Rengasamy**

Co-Founder of Biggworld company. Successful Networker and Million Dollar Club Inductee in USANA Health Sciences. Awarded, National Day Military Efficiency Medal during tour of duties with Republic of Singapore Air Force. A people's person networker with strong self driven entrepreneurship.